Imunon, Inc. ((IMNN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Imunon, Inc. is conducting a Phase II clinical study titled ‘Phase II Study Evaluating the Effect of IMNN-001 on Second Look Laparoscopy (SLL) in Combination With Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer.’ The study aims to assess the safety, dosing, efficacy, and biological activity of adding IMNN-001 to a standard chemotherapy regimen with BEV, compared to chemotherapy with BEV alone. This research is significant as it explores potential advancements in treatment for advanced ovarian and related cancers.
The intervention being tested is IMNN-001, an IL-12 plasmid formulated with PEG-PEI-Cholesterol lipopolymer, which is being added to the existing chemotherapy and BEV regimen. The intended purpose is to enhance the treatment’s effectiveness in combating advanced ovarian, fallopian tube, or primary peritoneal cancer.
The study is designed as a 1:1 randomized, open-label, multi-center trial. Participants are randomly assigned to either the experimental group receiving IMNN-001 with chemotherapy and BEV or the control group receiving only chemotherapy and BEV. There is no masking involved, and the primary purpose is treatment-focused.
The study began on February 10, 2023, and is currently recruiting participants. The primary completion date is yet to be announced, with the last update submitted on July 1, 2025. These dates are crucial for tracking the study’s progress and potential results.
The market implications of this study are significant for Imunon, Inc., as positive results could enhance their stock performance and attract investor interest. The study’s outcome could also influence the competitive landscape in the oncology sector, particularly in treatments for advanced ovarian cancer.
The study is ongoing, and further details are available on the ClinicalTrials portal.